Inhibition of CD82 improves colitis by increasing NLRP3 deubiquitination by BRCC3

Area of Science:

• Immunology
• Microbiology
• Cell Biology

Background:

• CD82 is a transmembrane protein involved in cancer suppression and immune cell activation.
• The role of CD82 in NLRP3 inflammasome regulation is not well understood.
• Inflammasomes, particularly NLRP3, are critical in inflammatory diseases like colitis.

Purpose of the Study:

• To investigate the role of CD82 in NLRP3 inflammasome activation and its impact on colitis.
• To identify CD82 binding partners involved in NLRP3 inflammasome regulation.
• To explore the therapeutic potential of Bacteroides vulgatus in colitis.

Main Methods:

• In vivo and in vitro experiments using mouse models of colitis.
• Identification of CD82 binding partners (NLRP3, BRCC3) using biochemical assays.
• Analysis of CD82 expression, NLRP3 inflammasome activation, and deubiquitination.
• Administration of Bacteroides vulgatus to mice with colitis.

Main Results:

• CD82 suppressed NLRP3 inflammasome activation, and CD82 deficiency ameliorated colitis severity.
• CD82 binds to NLRP3 and BRCC3, inhibiting NLRP3 degradation via blocking BRCC3-dependent deubiquitination.
• Bacteroides vulgatus administration increased survival in colitis mice by upregulating CD82 and activating NLRP3.

Conclusions:

• CD82 suppression reduces colitis pathogenesis by enhancing NLRP3 inflammasome activation through BRCC3-dependent K63 deubiquitination.
• Bacteroides vulgatus emerges as a potential novel therapeutic agent for colitis.